What COVID Taught Us About the Benefits of Cryopreservation for Cell-Based Therapies

COVID-19 cell illustration

The COVID-19 pandemic significantly impacted various sectors of healthcare, including the blood and biotherapies field. It disrupted the supply and demand for blood and blood-derived cell products, presenting unprecedented logistical challenges that underscored the benefit of cryopreservation for cell and gene therapies (CGT). According to the National Marrow Donor Program (NMDP), cryopreservation of hematopoietic progenitor […]

How the BioLife Solutions Master File Letter Request Process Works for CryoStor® and HypoThermosol® FRS

Cross-Referencing BioLife Master Files CryoStor and HypoThermosol FRS (HTS-FRS) are critical components in many customer cell and gene therapy (CGT) and regenerative medicine processes. Although they are not regulated medical products—meaning they are not classified as drugs, medical devices, or marketed/registered as excipients—they serve a critical role as ancillary/raw materials in cell-based manufacturing processes. BioLife […]

This website uses cookies to ensure you get the best experience on our website.